Haleon plc Buys Back Own Shares
Ticker: HLNCF · Form: 6-K · Filed: Sep 22, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-buyback, transaction
TL;DR
Haleon bought back its own stock on 9/22/25, likely a positive signal.
AI Summary
On September 22, 2025, Haleon plc reported a transaction in its own shares. The company purchased shares as part of its share buy-back program, with specific details of the transaction to be provided in Exhibit 99.1.
Why It Matters
Share buy-backs can indicate management's confidence in the company's valuation and can potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or strategic information.
Key Players & Entities
- Haleon plc (company) — Registrant
- 22 September 2025 (date) — Date of transaction
- 001-41411 (company) — SEC File Number
FAQ
What type of transaction did Haleon plc report on September 22, 2025?
Haleon plc reported a transaction in its own shares.
What is the SEC file number for Haleon plc?
The SEC file number for Haleon plc is 001-41411.
Under which rule is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Does Haleon plc file annual reports under Form 20-F or Form 40-F?
Haleon plc files annual reports under cover of Form 20-F.
What exhibit number contains the details of the transaction in own shares?
Exhibit Number 99.1 contains the details of the transaction in own shares.
Filing Stats: 580 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2025-09-22 06:52:36
Filing Documents
- a1368a000.htm (6-K) — 33KB
- a1368a000000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010961.txt ( ) — 39KB
From the Filing
IN OWN SHARES a1368a000 UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 22 September 2025 - Transaction in Own Shares     99.1     Haleon plc:   Transaction in own shares   22 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 4,150,000 ordinary shares of £0.01 each in the Company (the "Shares")   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 19 September 2025 19 September 2025 19 September 2025 Number of Shares purchased: 3,507,000 - 643,000 Highest price paid per Share (p): 342.3000 - 341.0000 Lowest price paid per Share (p): 338.8000 - 338.8000 Volume weighted average price paid per Share (p): 340.7178 - 340.1845   The Company intends to hold the purchased shares as treasury shares.   Following the settlement of the above, the Company's registered share capital   is 8,952,353,648 ordinary shares of £0.01 each, of which 23,037,545 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,929,316,103 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/1366A_1-2025-9-19.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .        SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 22, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary